FDA Approves First Gene Therapy to Treat Adults with Hemophilia B
Hemgenix (etranacogene dezaparvovec), an adeno-associated virus vector-based gene therapy, has been approved by the U.S. Food and Drug Administration for the treatment of adults with Haemophilia B (congenital factor IX deficiency) who are currently receiving Factor IX prophylaxis therapy, have…